ReviewCurrent opinion in pharmacology2021
Old and new biomarkers for volumetric muscle loss.
Review in Current opinion in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Aligned multicompartment collagen scaffolds support stratified myoblast and fibroblast behavior for musculotendinous tissue engineering.bioRxiv : the preprint server for biology · 2026Article
- Nanotechnology-mediated strategies for skeletal muscle repair and regeneration: targeted intervention, functional remodeling, and translational challenges.Journal of nanobiotechnology · 2026Review
- Electronic health record mining reveals effects of patient immune status on clinical outcomes of biomaterial implantation following skeletal muscle damage.Biomaterials science · 2026Article
- Mouse Models of Muscle Fibrosis: Mechanisms, Methods, and Applications.Biomedicines · 2026Review
- Biomimetic Scaffolds and Extracellular Matrix-Based Strategies for Myofiber Regeneration in Volumetric Muscle Loss.Drug design, development and therapy · 2026Review
- Electronic health record mining reveals effects of patient immune status on clinical outcomes of biomaterial implantation following skeletal muscle damage.medRxiv : the preprint server for health sciences · 2025Article
- Unveiling the Potential of Bioactive Glass in Volumetric Muscle Loss Regeneration.Materials (Basel, Switzerland) · 2025Review
- Cell-scale porosity minimizes foreign body reaction and promotes innervated myofiber formation after volumetric muscle loss.NPJ Regenerative medicine · 2025Article
- Biomaterial-Based Regenerative Strategies for Volumetric Muscle Loss: Challenges and Solutions.Advances in wound care · 2025Review
- The Impact of Persevering Home Full-Body In-Bed Gym Exercise on Body Muscles in Aging: A Case Report by Quantitative Radio-Densitometric Study Using 3D and 2D Color CT.Diagnostics (Basel, Switzerland) · 2024Article
- Tissue Engineered 3D Constructs for Volumetric Muscle Loss.Annals of biomedical engineering · 2024Review
- Platelet-derived chemokines promote skeletal muscle regeneration by guiding neutrophil recruitment to injured muscles.Nature communications · 2023Article
- Porous biomaterial scaffolds for skeletal muscle tissue engineering.Frontiers in bioengineering and biotechnology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Volumetric muscle loss (VML) impacts skeletal muscles and causes damage to associated tissues such as blood vessels and other structural tissues. Despite progress in the VML field, current preclinical approaches are often ineffective at restoring muscle volume. Additional research is paramount to develop strategies that improve muscle mass and function, while restoring supporting tissues. We highlight mechanisms that govern normal muscle function that are also key players for VML, including intracellular calcium signaling/homeostasis, mitochondria signaling (calcium, reactiove oxidative species (ROS)/oxidative stress), and angiogenesis. We propose an integration of these processes within the context of emerging biomaterials that provide structural support for muscle regeneration. We posit that new biomarkers (i.e. myokines and lipid signaling mediators) may serve as sentinels of early muscle injury and regeneration. We conclude that as new ideas, approaches, and models come together, new treatments will emerge to allow the full rebuilding of skeletal muscles and functional recovery of skeletal muscles after VML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.